BrUOG 379 Phase Ib/II Trial ONC201 + Nivolumab in MSS mCRC (379)

• ClinicalTrials.gov Identifier: NCT03791398
• Recruitment Status: Terminated
• First Posted: January 2, 2019
• Results First Posted: June 21, 2022
• Last Update Posted: February 17, 2023
• Sponsor: Brown University
• Collaborators: Rhode Island Hospital; Bristol-Myers Squibb; Oncoceutics, Inc.
• Information provided by (Responsible Party): Brown University

Study Description

Brief Summary:

This is a single arm Phase Ib/II, open label, safety, pharmacokinetic, pharmacodynamics and efficacy study of ONC201 in combination with Opdivo (Nivolumab) in adult patients with metastatic colorectal cancer, for whom no standard therapy is available. This study will enroll adult patients with metastatic colorectal cancer who progressed after at least two lines of therapy.

Condition or disease	Intervention/treatment	Phase
Metastatic Colorectal Cancer	Drug: Dose level 1 ONC201 625mg; Drug: Dose level 2 ONC201 500mg; Drug: Dose level 3 ONC201 375mg	Phase 1; Phase 2

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 13 participants
• Allocation: Non-Randomized
• Intervention Model: Single Group Assignment
• Intervention Model Description: This is a single arm study of de-escalating arms to determine the MTD and then expand the trial.It is not randomized.
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: BrUOG 379: A Phase Ib/II Single Arm Study of ONC201 Plus Nivolumab in Microsatellite Stable (MSS) Metastatic Colorectal Cancer (mCRC) Patients
• Actual Study Start Date: November 15, 2019
• Actual Primary Completion Date: June 16, 2021
• Actual Study Completion Date: August 5, 2021

Arms and Interventions

Arm	Intervention/treatment
Experimental: ONC201 Level 1 (Starting Dose Level); 625mg ONC201 Cycle 1 Day -7 dose then once week	Drug: Dose level 1 ONC201 625mg; ONC201 625mg + Nivolumab 240mg IV flat dose; Other Name: ONC201 + Nivolumab
Experimental: ONC201 Level 2; 500 mg ONC201 Cycle 1 Day -7 dose then once week	Drug: Dose level 2 ONC201 500mg; ONC201 500mg + Nivolumab 240mg IV flat dose; Other Name: ONC201 + Nivolumab
Experimental: ONC201 Level 3; 375 mg ONC201 Cycle 1 Day -7 dose then once week	Drug: Dose level 3 ONC201 375mg; ONC201 375mg + Nivolumab 240mg IV flat dose; Other Name: ONC201 + Nivolumab
Experimental: Nivolumab; 240mg IV flat dose q 2 weeks	Drug: Dose level 1 ONC201 625mg; ONC201 625mg + Nivolumab 240mg IV flat dose; Other Name: ONC201 + Nivolumab; Drug: Dose level 2 ONC201 500mg; ONC201 500mg + Nivolumab 240mg IV flat dose; Other Name: ONC201 + Nivolumab; Drug: Dose level 3 ONC201 375mg; ONC201 375mg + Nivolumab 240mg IV flat dose; Other Name: ONC201 + Nivolumab

Outcome Measures

Primary Outcome Measures :

1. Maximum Tolerated Dose of ONC201 With Nivolumab for Phase II [ Time Frame: Cycle 1 (each cycle is approximately 4 weeks) through pre-dosing cycle 2, approximately 1 month ]
2. Progression Free Survival [ Time Frame: From start of protocol therapy until death or progression, a maximum of 6 months from end of therapy. ]
   Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

1. Patients must have a histologically/cytologically -confirmed primary colorectal tumor, with confirmation of being microsatellite stable.
2. Radiographic or clinical evidence of metastatic disease that has progressed after at least 2 prior regimens. Prior bevacizumab, cetuximab, trifluridine and tipiracil , or regorafenib is allowed, prior FOLFIRI and FOLFOX treatment is required. (Treatment with a FOLFIRINOX regimen will count as 2 regimens). Prior treatment does not have to have been in the metastatic setting.
3. Patients must have measurable disease by RECIST criteria
4. All patients must have a tumor(s) located in an area that that can be biopsied as confirmed by treating physician
5. All patients must submit representative tissue from their malignancy if it is confirmed there is enough tissue from prior surgery or most recent biopsy.
6. All previous therapies for cancer, including radiotherapy, major surgery and investigational therapies must be discontinued for ≥ 14 days before the first dose of ONC201
7. All clinically significant adverse events related to any prior therapy must have resolved to Grade ≤ 1 Common Terminology Criteria for Adverse Events (CTCAE v5.0), except alopecia or parameters defined in this eligibility list.
8. Age ≥ 18 years.
9. ECOG performance status ≤ 2.

10. Adequate organ and marrow function as defined below:

    1. Absolute neutrophil count ≥1,000/mm3 without growth factor use ≤ 7 days prior to treatment
    2. Platelets ≥75,000/mm3 without platelet transfusion ≤ 7 days prior to treatment
    3. Hemoglobin>8.0 mg/dL without red blood cell transfusion ≤ 7 days prior to treatment
    4. Total serum bilirubin<1.5 X upper limit of normal (ULN)
    5. AST (SGOT)/ALT (SGPT)≤2 X ULN; ≤ 5 X ULN if liver dysfunction is felt to be secondary to tumor burden within 14 days prior to treatment, Serum creatinine ≤ 1.5 X ULN (OR creatinine clearance ≥ 60 mL/min/1.73 m2) within 14 days prior to treatment
    6. Serum or urine pregnancy test (for females of childbearing potential) negative ≤7 days of treatment
11. Ability to understand and the willingness to sign a written informed consent document and comply with the study scheduled visits, treatment plans, laboratory tests and other procedures.
12. Female patients of child-bearing potential must be practicing an effective form of contraception from the time of informed consent and for the duration of the study treatment through 5 months after the last dose of drug (ONC201 or Nivolumab, whichever is administered last). The decision of effective contraception will be based on the judgment of the principal investigator or a designated associate.
13. Male patients must be surgically sterile (provide date of surgery) or must agree to use effective contraception from the time of informed consent and for the duration of the study treatment through 7 months after the last dose of drug (ONC201 or Nivolumab, whichever is administered last). The decision of effective contraception will be based on the judgment of the principal investigator or a designated associate.
14. Patients must agree to the required tumor biopsies to enroll in the trial.

Exclusion Criteria:

1. Patients with symptomatic brain metastases are excluded. Patients with asymptomatic and treated CNS metastases may participate in this trial. The patient must have completed any prior treatment for CNS metastases > 28 days prior to registration, including radiotherapy or surgery. Steroids for the treatment of brain metastasis are not permitted.
2. Patients with prior treatment with ONC201 will be excluded
3. Active inflammatory gastrointestinal disease such as severe chronic diarrhea (unless related to underlying malignancy), gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to study registration. Gastroesophageal reflux disease under controlled treatment with proton pump inhibitors is allowed.
4. Pregnant or breast feeding.
5. Current active treatment in another clinical study (treatment trial) within 14 days of D-7.
6. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection requiring IV antibiotics, hepatitis, active rheumatologic or collagen vascular disease, symptomatic congestive heart failure, unstable angina pectoris, clinically significant cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
7. Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)-related illness. (testing is not required for eligibility).
8. Any of the following in the previous 3 months: myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident, transient ischemic attack or symptomatic pulmonary embolism as defined by treating physician.
9. Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration, or may interfere with the interpretation of study results, or in the judgment of the investigator would make the patient inappropriate for entry into the study.
10. Participants with an active, known or suspected autoimmune disease. Participants with type I diabetes mellitus, hypothyroidism only requiring hormone replacement, skin disorders (such as vitiligo, psoriasis, or alopecia) not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enroll.
11. Participants with a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of day 1 of treatment. Inhaled or topical steroids, and adrenal replacement steroid doses > 10 mg daily prednisone equivalent, are permitted in the absence of active autoimmune disease
12. Patients with a history of other invasive malignancies, with the exception of non-melanoma skin cancer are excluded if there is any evidence of other malignancy being present within the last three years (2 years for invasive breast cancer). However, patients with a malignancy that is non-likely to require treatment, as per the treating physician, in the next 2 years, such as a completely resected, early stage breast cancer, or other malignancies treated with curative intent are eligible. Patients are also excluded if their previous cancer treatment contraindicates this protocol therapy.
13. Prior treatment with immunotherapy for any cancer, including immune checkpoint inhibitors or anti-CTLA4 agents
14. Participants who have received a live / attenuated vaccine within 30 days of first treatment.

Contacts and Locations

Locations

United States, Rhode Island

Lifespan Cancer Institute: The Miriam and Rhode Island Hospitals

Providence, Rhode Island, United States, 02903

Sponsors and Collaborators

Brown University

Rhode Island Hospital

Bristol-Myers Squibb

Oncoceutics, Inc.

  Study Documents (Full-Text)

Documents provided by Brown University:

Study Protocol, Statistical Analysis Plan, and Informed Consent Form  [PDF] March 30, 2021

More Information

• Responsible Party: Brown University
• ClinicalTrials.gov Identifier: NCT03791398
• Other Study ID Numbers: BrUOG 379
• First Posted: January 2, 2019
• Results First Posted: June 21, 2022
• Last Update Posted: February 17, 2023
• Last Verified: February 2023

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No
• Product Manufactured in and Exported from the U.S.: No

Keywords provided by Brown University:

Metastatic; colorectal cancer; colon cancer; microsatellite stable

Additional relevant MeSH terms:

Colorectal Neoplasms; Intestinal Neoplasms; Gastrointestinal Neoplasms; Digestive System Neoplasms; Neoplasms by Site; Neoplasms; Digestive System Diseases; Gastrointestinal Diseases; Colonic Diseases; Intestinal Diseases; Rectal Diseases; Nivolumab; TIC10 compound; Antineoplastic Agents, Immunological; Antineoplastic Agents; Immune Checkpoint Inhibitors; Molecular Mechanisms of Pharmacological Action